Vikram C. Gorantla

Vikram Gorantla practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Vikram Gorantla's NPI, 1528220779, was assigned on June 30, 2008. Vikram Gorantla graduated from University of Texas Southwestern Medical School at Dallas in 2008. Vikram Gorantla holds Pennsylvania license MD443738.

Vikram Gorantla's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Vikram Gorantla's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Vikram Gorantla is also affiliated with UPMC Presbyterian. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Vikram Gorantla to 3 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Vikram Gorantla practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Vikram Gorantla's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Vikram Gorantla is licensed in Pennsylvania.

CMS data shows 1,138 Medicare services from Vikram Gorantla across 10 procedure codes in 2024, for 342 Medicare patients. Medicare paid $80,930 for them.

CMS counts 342 Medicare patients who saw Vikram Gorantla in 2024. The largest group is 65 to 74, with 182 patients. 71% of them have cancer, and 71% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Vikram Gorantla's median patient age at 72, with 73% women.

In 2024, Vikram Gorantla wrote 1,192 Medicare Part D claims for 306 patients. 89% of them were for generic drugs. CMS names the drug for 1,016 of them, across 16 drugs with 11 or more claims each, at $198,972 in total drug cost. In 2023, CMS named 1,004 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Vikram Gorantla for performance year 2024, reported as part of a group. Vikram Gorantla accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 16 papers to Vikram Gorantla, published from 2013 to 2025. 2020 was the busiest year, with 5. The most frequent topics are Melanoma, Neoadjuvant Therapy and Breast Neoplasms. Vikram Gorantla has published most often in JCO Oncol Pract. Vikram Gorantla's most frequent co-authors are Roby A. Thomas, Amer H. Zureikat, MD and Alessandro Paniccia.

Dmand AI links Vikram Gorantla to 1 clinical trial. Conditions studied include Neoplasm Metastasis and Neoplastic Processes.

CMS Open Payments shows 126 general payments to Vikram Gorantla from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. AstraZeneca Pharmaceuticals LP paid the most, $17,252.

Vikram Gorantla graduated from University of Texas Southwestern Medical School at Dallas in 2008.